3 drug(s) with this reaction
1,907 total reports
Therapeutic Response Decreased has been reported as an adverse reaction across 3 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 1,907 adverse event reports mention therapeutic response decreased in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with therapeutic response decreased, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have therapeutic response decreased listed in their FDA adverse event reports, sorted by report count:
In addition to therapeutic response decreased, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
3 drug(s) manufactured by Amgen Inc have therapeutic response decreased listed in their FDA adverse event reports: ROMIPLOSTIM, DARBEPOETIN ALFA, EPOETIN ALFA.
There are a combined 1,907 reports of therapeutic response decreased across 3 Amgen Inc drug(s) in the FDA adverse event database.